Diastolic Robotics' mission is to improve patient care. We want to:
To these ends Diastolic Robotics Incorporated (DRI) works in medicine and engineering, developing drug and device solutions.
Diastolic Robotics™ — also known as diarobo™ — was started to commercialize products in the surgical robotics space, specifically surgical tools for heart stabilization during coronary artery bypass procedures. One such device was THASA, the Tissue and Heart Stabilization Tool, which is described in United States patent:
THASA held sections of the heart still for coronary artery bypass grafting procedures, allowing work to progress off-pump.
Following THASA, DRI expanded into medical device consulting and software development. Some of the software projects included simulation and modelling programs:
Currently DRI's software projects include apps and other software for medical professionals. These projects include:
More recently, DRI has been commercializing products for individualizing drug therapies, specifically neuromuscular blockers (NMB) but with many other indications in mind, and other projects in anesthesia. NMB drugs are safe, but subject to frequent incidences of under- and overdosing due to dose-by-weight regimens. We have a solution that reduces these incidences, as we demonstrated in a 60 patient clinical trial. Please view the NMB Projects page for the details.
DRI has also been working on other anesthesia products and projects. Please see the Products for Anesthesia page for the details.
diarobo and "Diastolic Robotics" are trademarks of Diastolic Robotics Incorporated
© 2012 Diastolic Robotics Incorporated